# SiliconANGLE — Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI

- Company: SiliconANGLE (siliconangle.com)
- Announced: 2026-11-17T23:51:11+00:00
- Category: funding-company-news
- Coverage: not counted
- Announcement: yes
- Group: announcements
- Source: https://siliconangle.com/2026/11/17/alphabets-isomorphic-labs-raises-5b-to-accelerate-drug-discovery-with-ai/
- Record: https://forck.live/items/37677-alphabet-s-isomorphic-labs-raises-5b-to-accelerate-drug-discovery-with-ai
- Subject: Reporting

Alphabet's Isomorphic Labs has closed a $5 billion investment led by Greenoaks and Sequoia Capital to speed up AI-driven drug discovery. More than a half-dozen backers joined the round, including parent Alphabet, which the company says made a "significant investment" through its GV and CapitalG funds. Isomorphic offers a software platform called the Isomorphic Labs Drug Design Engine, or IsoDDE, which uses AI to speed up several tasks in developing new medicines, and the unit says multiple pharmaceutical companies already use it to power drug discovery programs. IsoDDE speeds up the search for binding pockets on a target protein and, when none exist, helps researchers develop compounds that cause the protein to form them. The software also skips the step of creating 3D protein models for FEP algorithms, which requires freezing a protein in a crystal and scanning it with X-ray equipment, and Isomorphic says it can generate higher-quality output than FEP. Chief Executive Demis Hassabis said the round lets the company build foundational biology models, deepen its disease understanding and drive its first therapeutic programs toward clinical trials. Isomorphic added that it plans to build new bioengineering infrastructure and grow its partner ecosystem.

## Evidence

Verbatim from https://siliconangle.com/2026/11/17/alphabets-isomorphic-labs-raises-5b-to-accelerate-drug-discovery-with-ai/:

> Isomorphic Labs Ltd. today announced that it has closed a $5 billion investment led by Greenoaks and Sequoia Capital.
> 
> The venture capital firms were joined by more than a half-dozen other backers. The group included Isomorphic parent Alphabet Inc., which made a “significant investment.” The search giant provided the capital through its GV and CapitalG startup funds.
> 
> Isomorphic offers a software platform called the Isomorphic Labs Drug Design Engine, or IsoDDE for short. It uses artificial intelligence to speed up several of the tasks involved in developing new medicines. The Alphabet unit says that multiple pharmaceutical companies are already using IsoDDE to power drug discovery programs.
> 
> Pathogens such as viruses comprise numerous proteins that each power a different biological process. Drugs work by neutralizing a single, particularly important protein without which the pathogen can’t function. Developing a new drug requires researchers to find a vulnerable protein within a pathogen and then develop a compound that can effectively target it.
> 
> The first step of the workflow is mapping out the shape of a target protein.

---

Record: https://forck.live/items/37677-alphabet-s-isomorphic-labs-raises-5b-to-accelerate-drug-discovery-with-ai
Catalogue: https://forck.live/llms.txt
Current issue: https://forck.live/feed.md
